[HTML][HTML] Lung cancer immunotherapy: progress, pitfalls, and promises

A Lahiri, A Maji, PD Potdar, N Singh, P Parikh, B Bisht… - Molecular cancer, 2023 - Springer
Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

[HTML][HTML] Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

VD de Jager, W Timens, A Bayle, J Botling… - The Lancet Regional …, 2024 - thelancet.com
For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies
have changed significantly due to the introduction of targeted therapies and immunotherapy …

Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer

NI Vokes, K Pan, X Le - Therapeutic advances in medical …, 2023 - journals.sagepub.com
For advanced metastatic non-small-lung cancer, the landscape of actionable driver
alterations is rapidly growing, with nine targetable oncogenes and seven approvals within …

[HTML][HTML] Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells

H Zhou, L Zhou, Q Guan, X Hou, C Wang, L Liu… - Communications …, 2023 - nature.com
Non-small cell lung cancer (NSCLC) is the most prevalent type of cancer and the leading
cause of cancer-related death. Chemotherapeutic resistance is a major obstacle in treating …

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions

J Zhong, H Bai, Z Wang, J Duan, W Zhuang… - Frontiers of …, 2023 - Springer
With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC),
expanding the targeted therapeutic options improved the survival and safety. However …

[HTML][HTML] HER2 alterations in non-small cell lung cancer: biologico-clinical consequences and interest in therapeutic strategies

E Loeffler, J Ancel, V Dalstein, G Deslée, M Polette… - Life, 2023 - mdpi.com
Lung cancer stands as the first cause of death by cancer in the world. Despite the
improvement in patients' outcomes in the past decades through the development of …

[HTML][HTML] Sex-specific differences in immunogenomic features of response to immune checkpoint blockade

SC Scott, XM Shao, N Niknafs, A Balan… - Frontiers in …, 2022 - frontiersin.org
Introduction The magnitude of response to immune checkpoint inhibitor (ICI) therapy may be
sex-dependent, as females have lower response rates and decreased survival after ICI …

[HTML][HTML] Quantifying the value of multigene testing in resected early stage lung adenocarcinoma

B Muthusamy, K Raskina, KT Lofgren, G Li… - Journal of Thoracic …, 2023 - Elsevier
Introduction Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs), each
requiring testing for precision biomarkers, have recently been approved in the adjuvant …

[HTML][HTML] Treatment of advanced non-small cell lung cancer with RET fusions: reality and hopes

D Rocco, L Sapio, L Della Gravara, S Naviglio… - International Journal of …, 2023 - mdpi.com
RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib have
revolutionized the landscape of RET-positive (RET+) advanced non-small cell lung cancer …

[HTML][HTML] An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy

S Verma, D Breadner, A Mittal, DA Palma, R Nayak… - Cancers, 2024 - mdpi.com
Simple Summary The recent evidence shows that patients with resectable non-small cell
lung cancer (NSCLC) benefit from the addition of immunotherapy to chemotherapy before …